---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-003949"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-11-25T23:59:59+00:00"
generated_at: "2026-05-16T17:05:15.564269+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Silexion completes toxicology studies for SIL204; Phase 2/3 trial on track for Q2 2026

## Summary
- Two-species toxicology studies for SIL204 confirm no systemic organ toxicity, clearing path to regulatory filings.
- Regulatory submissions planned to Israel Ministry of Health and Germany's BfArM ahead of Phase 2/3 trial.
- Phase 2/3 clinical trial in locally advanced pancreatic cancer (LAPC) expected to initiate in Q2 2026.
- CRO partner for the trial has been secured; SIL204 targets mutant KRAS oncogenes via siRNA.

## SEC filing metadata
- accession: 0001178913-25-003949
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-11-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003949/0001178913-25-003949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003949/zk2534066.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-003949
- JSON: https://secwatch.observer/filing/0001178913-25-003949.json
- Plain text: https://secwatch.observer/filing/0001178913-25-003949.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.